Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study

BACKGROUND: Experimental CCR5 antagonism with maraviroc in atherosclerosis-prone mice and preliminary data in humans suggest an anti-atherosclerotic effect of the drug. We assessed the impact of maraviroc treatment in persons living with HIV on subclinical indicators of atherosclerosis. METHODS: Per...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Open Forum Infect Dis
Main Authors: Francisci, Daniela, Pirro, Matteo, Schiaroli, Elisabetta, Mannarino, Massimo R, Cipriani, Sabrina, Bianconi, Vanessa, Alunno, Alessia, Bagaglia, Francesco, Bistoni, Onelia, Falcinelli, Emanuela, Bury, Loredana, Gerli, Roberto, Mannarino, Elmo, De Caterina, Raffaele, Baldelli, Franco
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
Major Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6446135/
https://ncbi.nlm.nih.gov/pubmed/30968058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz112
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares